We are live on ! Find out more

Passage Bio

PASG

Market cap $12.8M

3.98 USD

+0.52

15.03%

At close Updated Nov 6, 4:00 PM EST

1 day

15.03%

5 days

15.36%

1 month

-2.45%

3 months

-9.55%

6 months

-3.4%

Year to date

-65.95%

1 year

-38.86%

5 years

-97.76%

10 years

-99.1%

About: Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Employees: 24

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the proposed transaction, Passage Bio shareholders are expected to own approximately 7% of the combined company. Halper Sadeh encourages Passage Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.

PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating:

$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD

Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

Passage Bio and Remix Therapeutics Announce Merger Agreement

Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Passage Bio and Remix Therapeutics Announce Merger Agreement

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Advancing differentiated preclinical program for Huntington's with clinical candidate selection expected in 2H 2026 Cash runway through 1Q 2027 PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. “We are proud of the progress made in 2025 as we meaningfully advanced our PBFT02 clinical program for the treatment of genetic forms of frontotemporal dementia,” said Will Chou, M.D.

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Format: Management will participate in a presentation and investor meetingsDate: Thursday, February 26, 2026Presentation Time: 8:40 a.m. ETLocation: Virtual TD Cowen 46 th Annual Health Care Conference Format: Management will participate in a presentation and investor meetingsDate: Wednesday, March 4, 2026Presentation Time: 1:50 p.m.

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process On track to obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Cash runway into 1Q 2027 PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “We are pleased to report that we have opened enrollment in our third FTD-GRN and first FTD-C9orf72 patient cohorts in our ongoing upliFT-D clinical trial of PBFT02.

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA.

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a panel discussion during the Chardan 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 3:30 p.m. ET in New York City.

Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

See News Rankings

Price charts implemented using Lightweight Charts™